BioMarin Reports Q1 2026 Earnings with Revenue Growth and Guidance Update
BioMarin (BMRN) reported Q1 2026 revenue of $766 million, driven by enzyme therapies and Voxogo, though offset by lower revenue from Rocktadian and Kuvan. The company raised its 2026 revenue guidance to $3.825 billion to $3.925 billion, projecting around 20% growth at the midpoint.
Topics: Cost of Sales EPS Guidance Pipeline Development R&D Expenses Revenue Growth